US010052286B2

(12) **United States Patent**
Villa et al.

(10) **Patent No.: US 10,052,286 B2**
(45) **Date of Patent: *Aug. 21, 2018**

(54) **CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION**

(71) Applicant: **COSMO TECHNOLOGIES LIMITED**, Dublin (IE)

(72) Inventors: **Roberto Villa**, Lecco (IT); **Massimo Pedrani**, Gignese (IT); **Mauro Ajani**, Milan (IT); **Lorenzo Fossati**, Milan (IT)

(73) Assignee: **COSMO TECHNOLOGIES LIMITED**, Dublin (IE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/646,585**

(22) Filed: **Jul. 11, 2017**

(65) **Prior Publication Data**

US 2017/0304209 A1 Oct. 26, 2017

Related U.S. Application Data

(63) Continuation of application No. 15/368,911, filed on Dec. 5, 2016, which is a continuation of application No. 15/202,962, filed on Jul. 6, 2016, now Pat. No. 9,592,203, which is a continuation of application No. 14/832,845, filed on Aug. 21, 2015, now abandoned, which is a continuation of application No. 14/491,363, filed on Sep. 19, 2014, now Pat. No. 9,192,581, which is a continuation of application No. 13/585,190, filed on Aug. 14, 2012, now Pat. No. 9,132,093, which is a continuation-in-part of application No. 13/226,758, filed on Sep. 7, 2011, now Pat. No. 8,895,064.

(51) **Int. Cl.**

A61K 9/20	(2006.01)
A61K 9/28	(2006.01)
A61K 9/24	(2006.01)
A61K 31/58	(2006.01)
A61K 9/00	(2006.01)
A61K 9/16	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 9/2081*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 9/209*** (2013.01); ***A61K 9/2013*** (2013.01); ***A61K 9/2018*** (2013.01); ***A61K 9/2027*** (2013.01); ***A61K 9/2054*** (2013.01); ***A61K 9/2077*** (2013.01); ***A61K 9/28*** (2013.01); ***A61K 9/282*** (2013.01); ***A61K 9/2813*** (2013.01); ***A61K 9/2846*** (2013.01); ***A61K 9/2866*** (2013.01); ***A61K 31/58*** (2013.01); *A61K 9/1617* (2013.01); *A61K 9/1652* (2013.01); *A61K 9/2045* (2013.01); *H05K 999/99* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,133,863	A	5/1964	Tansey et al.	
3,800,051	A	3/1974	Barnhart et al.	
3,965,256	A	6/1976	Leslie	
4,608,248	A	8/1986	Knecht et al.	
4,716,041	A	12/1987	Kjornaes et al.	
5,183,815	A	2/1993	Saari et al.	
5,320,848	A	6/1994	Geyer et al.	
5,342,625	A	8/1994	Hauer et al.	
5,447,729	A	9/1995	Belenduik et al.	
5,472,711	A	12/1995	Baichwal	
5,534,501	A	7/1996	Samain et al.	
5,541,170	A	7/1996	Rhodes et al.	
5,597,844	A	1/1997	Chauhan et al.	
5,643,602	A	7/1997	Ulmius	
5,681,584	A *	10/1997	Savastano	A61K 9/0004 424/468
5,741,524	A	4/1998	Staniforth et al.	
5,811,388	A *	9/1998	Friend	A61K 9/205 424/465
5,840,332	A	11/1998	Lerner et al.	
5,849,327	A	12/1998	Berliner et al.	

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2119253	11/1998
CA	2274943 A1	12/1999

(Continued)

OTHER PUBLICATIONS

L. Borgström et al. "Lung deposition of budesonide inhaled via Turbuhaler®: A comparison with terbutaline sulphate in normal subjects," Eur. Respir. J., 7:69-73 (1994)—pages.

(Continued)

Primary Examiner — Susan T Tran

(74) *Attorney, Agent, or Firm* — Rothwell, Figg, Ernst & Manbeck, P.C.

(57) **ABSTRACT**

Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

22 Claims, No Drawings